No Data
No Data
No Data
No Data
No Data
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersXTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 95.8% to $2.04 during Wednesday's regular session. The company's market cap stands at $11.0 million. Etao International Co (NASDAQ:E
BenzingaMar 20 13:31 ET
Optimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial Results
TipRanksMar 20 05:56 ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersOntrak (NASDAQ:OTRK) shares increased by 97.6% to $0.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.3 million. Fusion Pharmaceuticals (NASDAQ:FUSN)
BenzingaMar 19 13:31 ET
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
Tuesday, Seelos Therapeutics Inc (NASDAQ:SEEL) provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial. The study was designed to evaluate SLS-005 (IV trehalose), a low molecula
BenzingaMar 19 09:38 ET
Express News | Seelos Therapeutics Shares Are Trading Lower After the Company Announced That Its ALS Study With SLS-005 Did Not Meet Statistical Significance in the Primary and Secondary Endpoint in the Full Analysis Set
Moomoo 24/7Mar 19 09:24 ET
Seelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary Endpoints
By Chris Wack Seelos Therapeutics shares were down 47% to 48 cents in premarket trading after a Phase 2/3 trial for SLS-005 for amyotrophic lateral sclerosis failed to meet its primary endpoints. Th
WSJMar 19 09:21 ET
No Data
No Data
TrytosaveabitOP : While the study did not meet statistical significance in the primary and secondary endpoint in the Full Analysis Set (FAS)2, by showing a 13% improvement in Function and Mortality with an 88% success probability (versus the pre-specified 98%), it showed a potential signal of efficacy in a pre-specified subgroup (ERF)1.